Home › Funds › RA CAPITAL MANAGEMENT, L.P. › SPRY
RA CAPITAL MANAGEMENT, L.P. position in SPRY
ARS PHARMACEUTICALS INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 10,860,977 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$46.8M, representing 0.48% of its reported portfolio and ranking #36 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed SPRY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s SPRY position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in SPRY in Q3 2023 at 9,459,678 shares (US$35.8M). The position peaked in Q2 2025 at 10,860,977 shares, worth US$189.5M. Across 13 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 11 time(s). The most recent filing (Q3 2026) shows 10,860,977 shares valued at US$46.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.46M | $35.76M | New |
| Q4 2023 | 9.46M | $51.84M | Hold |
| Q1 2024 | 10.86M | $111.00M | Add |
| Q2 2024 | 10.86M | $92.43M | Hold |
| Q3 2024 | 10.86M | $157.48M | Hold |
| Q4 2024 | 10.86M | $114.58M | Hold |
| Q1 2025 | 10.86M | $136.63M | Hold |
| Q2 2025 | 10.86M | $189.52M | Hold |
| Q3 2025 | 10.86M | $109.15M | Hold |
| Q4 2025 | 10.86M | $126.53M | Hold |
| Q1 2026 | 10.86M | $87.21M | Hold |
| Q2 2026 | 10.86M | $87.00M | Hold |
| Q3 2026 | 10.86M | $46.81M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 19 other funds we track also report a position in SPRY — the largest reported positions include ORBIMED ADVISORS LLC (US$35.7M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$32.3M), SR ONE CAPITAL MANAGEMENT, LP (US$17.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- ORBIMED ADVISORS LLC 8.29M sh · $35.72M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $32.34M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $17.30M · Q3 2026
- Tyro Capital Management LLC 3.20M sh · $13.79M · Q3 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held SPRY?
RA CAPITAL MANAGEMENT, L.P. has disclosed SPRY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in SPRY?
As of Q3 2026, RA CAPITAL MANAGEMENT, L.P. holds 10.86M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $46.81M, representing 0.48% of its reported portfolio and ranking #36.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling SPRY?
In the latest 13F filing (Q3 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in SPRY. The position peaked in Q2 2025 at 10.86M shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include ORBIMED ADVISORS LLC, DEERFIELD MANAGEMENT COMPANY, L.P., SR ONE CAPITAL MANAGEMENT, LP, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.